Revvity showcases cutting-edge solutions at SLAS2024

Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held in Boston from February 3-7 in booth #408.

The latest product introductions and technological synergies across its portfolio, which are designed to spur scientific advancement and drive efficiencies in drug development – with a special emphasis on the innovation and discovery phase - will be featured throughout at its exhibit and in several talks and poster presentations.

Innovation in Focus

As the landscape of medicine becomes more personalized, Revvity aims to provide high-value, cutting-edge solutions that foster scientific innovation and positively impact human health. Its offerings are designed to provide differentiated capabilities, providing customers with tools needed for success in precision medicine and beyond.

Dr. Alan Fletcher, Revvity’s senior vice president, life sciences, stated, "We're here in our backyard showing how we're seamlessly bringing it all together, powering innovation from research to reality. Our approach and products are centered around assisting scientists in discovering more and translating faster in clinical development, drug discovery, and basic research.” Revvity serves as a scientific partner for preclinical research and development, GMP manufacturing, global genomic labs, and leading clinical diagnostics.

Highlights at SLAS 2024

Revvity will be exhibiting a selection of its extensive range of life sciences and diagnostics products and services.

  • New Modalities: Technologies and services to design, deliver and analyze genetic payloads helping to expand the frontiers of research, including Pin-point™ base editing, AAV engineering and optimization +AAV process development services, LentiBOOST® GMP-grade transduction enhancer and a range of gene modification technologies. Also on display is the Company's newly launched LabChip® AAV empty/full characterization solution for gene therapy applications, adding to its genomics and proteomics analysis capabilities. This AAV assay offers important ease of use and throughput advantages over traditional AAV analysis methods.
  • Automation Technologies: Integrated robotics and software solutions for increased productivity that include systems such as: chemagic™ 360 nucleic acid extraction system, Explorer™ G3 workstation with integrated Fontus™ liquid handler, FlexDrop™ iQ™ non-contact dispenser and Omni™ LH 96 automated homogenization workstation.
  • Cellular Technologies: Advanced technologies for cell analysis, which can enable research and discovery breakthroughs including: Cellaca® PLX image cytometry system, Opera Phenix® HCS system, Signals Image Artist™ software, CRISPR and RNAi reagents, cell painting assays and the extensive range of BioLegend® antibodies for flow cytometry.
  • Omics: Comprehensive platforms for accelerated multiomic discoveries that include: Single cell proteogenomic assays and Omni™ Bead Ruptor™ solution for tissue homogenization.
  • Precision Medicine and Diagnostics: Tailored diagnostic-enabling and discovery technologies for improved patient outcomes including: BioLegend® reagents for flow cytometric cell phenotyping, BioQule™ NGS system for automated sample in - library out preparation, CDX assay development services, ELISPOT® secreted protein detection assays including the T-SPOT® latent TB screening test and MojoSort™ magnetic cell separation system.
  • Assay Development: Advanced solutions designed to increase throughput and precision of assays are in the spotlight and include: Dharmacon® reagents, including CRISPR/RNAi screening libraries, as well as services spanning functional genomics, cell panel and immune cell screening, as well as CRISPR-based cell line engineering. Revvity’s no-wash immunoassays and its detection and cellular imaging portfolios will be on display, including Revvity’s EnVision® Nexus™ Multimode microplate reader and IVIS® and Vega® in vivo imaging platforms.

For more information on Revvity, these innovative solutions that will be showcased at SLAS, as well as various presentations and scientific posters that feature Revvity and its products, visit booth #408 and the SLAS2024 events page.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Revvity. (2024, July 18). Revvity showcases cutting-edge solutions at SLAS2024. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20240205/Revvity-showcases-cutting-edge-solutions-at-SLAS2024.aspx.

  • MLA

    Revvity. "Revvity showcases cutting-edge solutions at SLAS2024". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20240205/Revvity-showcases-cutting-edge-solutions-at-SLAS2024.aspx>.

  • Chicago

    Revvity. "Revvity showcases cutting-edge solutions at SLAS2024". News-Medical. https://www.news-medical.net/news/20240205/Revvity-showcases-cutting-edge-solutions-at-SLAS2024.aspx. (accessed October 31, 2024).

  • Harvard

    Revvity. 2024. Revvity showcases cutting-edge solutions at SLAS2024. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20240205/Revvity-showcases-cutting-edge-solutions-at-SLAS2024.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PerkinElmer to Acquire Antibody and Reagent Leader BioLegend